WO2008005456A3 - Fused heterocyclic inhibitors of d-amino acid oxidase - Google Patents

Fused heterocyclic inhibitors of d-amino acid oxidase Download PDF

Info

Publication number
WO2008005456A3
WO2008005456A3 PCT/US2007/015396 US2007015396W WO2008005456A3 WO 2008005456 A3 WO2008005456 A3 WO 2008005456A3 US 2007015396 W US2007015396 W US 2007015396W WO 2008005456 A3 WO2008005456 A3 WO 2008005456A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid oxidase
fused heterocyclic
heterocyclic inhibitors
compounds
Prior art date
Application number
PCT/US2007/015396
Other languages
French (fr)
Other versions
WO2008005456A2 (en
Inventor
James M Dorsey
Seth C Hopkins
Robert J Foglesong
Michele L R Heffernan
Michael L Jones
Joseph B Perales
Qun Kevin Fang
Cyprian O Ogbu
Steven W Jones
Mustapha Soukri
Mark A Varney
Kerry L Spear
Original Assignee
Sepracor Inc
James M Dorsey
Seth C Hopkins
Robert J Foglesong
Michele L R Heffernan
Michael L Jones
Joseph B Perales
Qun Kevin Fang
Cyprian O Ogbu
Steven W Jones
Mustapha Soukri
Mark A Varney
Kerry L Spear
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc, James M Dorsey, Seth C Hopkins, Robert J Foglesong, Michele L R Heffernan, Michael L Jones, Joseph B Perales, Qun Kevin Fang, Cyprian O Ogbu, Steven W Jones, Mustapha Soukri, Mark A Varney, Kerry L Spear filed Critical Sepracor Inc
Priority to CA002659060A priority Critical patent/CA2659060A1/en
Priority to EP07796659A priority patent/EP2057162A2/en
Priority to BRPI0713216-6A priority patent/BRPI0713216A2/en
Priority to MX2008016525A priority patent/MX2008016525A/en
Priority to AU2007269646A priority patent/AU2007269646A1/en
Priority to JP2009518342A priority patent/JP2009542683A/en
Publication of WO2008005456A2 publication Critical patent/WO2008005456A2/en
Priority to TW097115422A priority patent/TW200906833A/en
Publication of WO2008005456A3 publication Critical patent/WO2008005456A3/en
Priority to IL195921A priority patent/IL195921A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. Also provided are methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure wherein Q is a member selected from O, S, CR1 and N, X and Y are members independently selected from CR2, O, S, N and NR3.
PCT/US2007/015396 2006-06-30 2007-07-02 Fused heterocyclic inhibitors of d-amino acid oxidase WO2008005456A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002659060A CA2659060A1 (en) 2006-06-30 2007-07-02 Fused heterocyclic inhibitors of d-amino acid oxidase
EP07796659A EP2057162A2 (en) 2006-06-30 2007-07-02 Fused heterocyclic inhibitors of d-amino acid oxidase
BRPI0713216-6A BRPI0713216A2 (en) 2006-06-30 2007-07-02 fused heterocyclic d-amino acid oxidase inhibitors
MX2008016525A MX2008016525A (en) 2006-06-30 2007-07-02 Fused heterocyclic inhibitors of d-amino acid oxidase.
AU2007269646A AU2007269646A1 (en) 2006-06-30 2007-07-02 Fused heterocyclic inhibitors of D-amino acid oxidase
JP2009518342A JP2009542683A (en) 2006-06-30 2007-07-02 Condensed heterocyclic inhibitors of D-amino acid oxidase
TW097115422A TW200906833A (en) 2007-04-26 2008-04-25 Fused heterocyclic inhibitors of D-amino acid oxidase
IL195921A IL195921A0 (en) 2006-06-30 2008-12-14 Fused heterocyclic inhibitors of d-amino acid oxidase

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US80639106P 2006-06-30 2006-06-30
US60/806,391 2006-06-30
US84246506P 2006-09-05 2006-09-05
US60/842,465 2006-09-05
US91429307P 2007-04-26 2007-04-26
US60/914,293 2007-04-26

Publications (2)

Publication Number Publication Date
WO2008005456A2 WO2008005456A2 (en) 2008-01-10
WO2008005456A3 true WO2008005456A3 (en) 2008-07-31

Family

ID=38877507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/015396 WO2008005456A2 (en) 2006-06-30 2007-07-02 Fused heterocyclic inhibitors of d-amino acid oxidase

Country Status (9)

Country Link
EP (1) EP2057162A2 (en)
JP (1) JP2009542683A (en)
KR (1) KR20090024823A (en)
AU (1) AU2007269646A1 (en)
BR (1) BRPI0713216A2 (en)
CA (1) CA2659060A1 (en)
IL (1) IL195921A0 (en)
MX (1) MX2008016525A (en)
WO (1) WO2008005456A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548212A (en) 2003-12-29 2010-07-30 Sepracor Inc Pyrrole and pyrazole DAAO inhibitors
NZ569608A (en) 2006-01-06 2011-09-30 Sepracor Inc Tetralone-based monoamine reuptake inhibitors
EP1976513B1 (en) 2006-01-06 2016-08-24 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
US8097760B2 (en) 2006-03-31 2012-01-17 Sunovion Pharmacuticals Inc. Preparation of chiral amides and amines
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
WO2008047821A1 (en) * 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
MX2009012685A (en) 2007-05-31 2009-12-14 Sepracor Inc Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors.
AR076766A1 (en) 2009-05-14 2011-07-06 Japan Tobacco Inc AZETIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND ITS USE IN THE TREATMENT OF AUTOIMMUNE DISEASES.
GB201111705D0 (en) * 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (en) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co Pyridazinone Compounds and Their Use as DAAO Inhibitors
GB201222711D0 (en) * 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
IL248567B (en) * 2014-04-30 2022-08-01 Univ Nat Taiwan Use of known compounds as d-amino acid oxidase inhibitors

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040914A1 (en) * 1998-02-17 1999-08-19 Astrazeneca Uk Limited Bicyclic pyrrole derivatives as mcp-1 inhibitors
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
EP1391460A1 (en) * 1999-09-30 2004-02-25 Pfizer Products Inc. Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors
WO2004022537A2 (en) * 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2005066135A2 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole daao inhibitors
WO2006004040A1 (en) * 2004-07-01 2006-01-12 Daiichi Asubio Pharma Co., Ltd. Thienopyrazole derivative having pde7 inhibitory activity
WO2006077412A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
WO2007039773A1 (en) * 2005-10-06 2007-04-12 Merck Sharp & Dohme Limited Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as d-amino acid oxidase inhibitors
WO2007068621A1 (en) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Novel fused pyrrole derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1088824E (en) * 1999-09-30 2004-04-30 Pfizer Prod Inc BLYCYLIC PYRROLYL-AMIDES AS GLYCOGENE-PHOSPHORYLASE INHIBITORS

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040914A1 (en) * 1998-02-17 1999-08-19 Astrazeneca Uk Limited Bicyclic pyrrole derivatives as mcp-1 inhibitors
EP1391460A1 (en) * 1999-09-30 2004-02-25 Pfizer Products Inc. Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
WO2004022537A2 (en) * 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2005066135A2 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole daao inhibitors
WO2006004040A1 (en) * 2004-07-01 2006-01-12 Daiichi Asubio Pharma Co., Ltd. Thienopyrazole derivative having pde7 inhibitory activity
WO2006077412A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
WO2007039773A1 (en) * 2005-10-06 2007-04-12 Merck Sharp & Dohme Limited Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as d-amino acid oxidase inhibitors
WO2007068621A1 (en) * 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Novel fused pyrrole derivatives

Also Published As

Publication number Publication date
WO2008005456A2 (en) 2008-01-10
AU2007269646A1 (en) 2008-01-10
IL195921A0 (en) 2009-09-01
EP2057162A2 (en) 2009-05-13
JP2009542683A (en) 2009-12-03
KR20090024823A (en) 2009-03-09
BRPI0713216A2 (en) 2012-12-04
MX2008016525A (en) 2009-03-09
CA2659060A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2008005456A3 (en) Fused heterocyclic inhibitors of d-amino acid oxidase
WO2006039718A3 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
WO2007064553A3 (en) Thiazole derivatives as cxcr3 receptor modulators
WO2008036540A3 (en) Rho kinase inhibitors
WO2007137103A3 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2008045393A3 (en) Imidazo- and triazolo-pyridine compounds and methods of use therof
HK1135103A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
WO2007070433A3 (en) 2-arylthiazole derivatives as cxcr3 receptor modulators
BRPI0513405A (en) thienopyrimidines useful as aurora kinase inhibitors
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
NO20071050L (en) Rapamycin polymorph II and uses thereof
WO2007059257A8 (en) N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
WO2007137107A3 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2007079199A3 (en) Substituted bis-amide metalloprotease inhibitors
WO2005046603A3 (en) Pyridine compounds
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
WO2007076092A3 (en) Nitrogen- containing bicyclic hetroaryl compounds for the treatment of raf protein kinase-mediated diseases
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
WO2008049123A8 (en) 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2008073687A3 (en) Compounds and compositions as protein kinase inhibitors
WO2005121130A3 (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
MX2009011754A (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme.
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780032007.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007269646

Country of ref document: AU

Ref document number: 573475

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2659060

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 195921

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/016525

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009518342

Country of ref document: JP

Ref document number: 10652/DELNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007269646

Country of ref document: AU

Date of ref document: 20070702

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007796659

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097001738

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009103008

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0713216

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081230